IgAN
47 programs · 46 companies
Programs
47
Companies
46
Trials
41
MOAs
34
CD47iBiTEAnti-TauTYK2iIL-17iCAR-T CD19JAK1/2iFXIaiPD-1iVEGFi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ceviglumide | NDA/BLA | B7-H3 | ||
| Zanutinib | Phase 2/3 | APOC3 | ||
| NVO-9630 | Phase 2 | CD3 | ||
| Voxacagene | Phase 2/3 | SOS1 | ||
| Rimaglumide | Phase 1/2 | BCL-2 | ||
| BII-4342 | Phase 2/3 | CGRP | ||
| Niramavacamten | Phase 2 | SGLT2 | ||
| IDY-3466 | NDA/BLA | Nectin-4 | ||
| EXA-971 | Phase 2 | CGRP | ||
| Tezesertib | Phase 1 | BCMA | ||
| Adagravorutinib | Phase 3 | IL-23 | ||
| NCI-IIT-878 | Approved | FGFR | ||
| STA-IIT-542 | Phase 2/3 | CFTR | ||
| RIN-582 | Phase 3 | SMN2 | ||
| Surafotisoran | Phase 2 | APOC3 | ||
| Nidafutibatinib | NDA/BLA | EZH2 | ||
| Olpaosocimab | NDA/BLA | CD47 | ||
| Fixafutibatinib | Preclinical | SMN2 | ||
| Kematenlimab | Phase 2/3 | CD3 | ||
| Lirasacituzumab | Preclinical | PCSK9 | ||
| Polazasiran | Phase 3 | KIF18A | ||
| Adagrazumab | Phase 1 | FGFR | ||
| NGM-3123 | Phase 3 | FcRn | ||
| Polazumab | Phase 3 | KRASG12D | ||
| Bemazanubrutinib | Phase 2/3 | AuroraA | ||
| Rimaratamab | Phase 2 | IL-17A | ||
| DER-2537 | Phase 2/3 | PSMA | ||
| Mavuinavolisib | Phase 1 | IL-23 | ||
| BIO-7835 | Phase 1/2 | USP1 | ||
| PBL-710 | Approved | ALK | ||
| Nidazumab | Phase 2 | CFTR | ||
| Elrasertib | Phase 3 | TIGIT | ||
| Zoricilimab | Phase 2 | SOS1 | ||
| Zanutenlimab | Phase 2 | CFTR | ||
| Adagraderotide | Phase 1/2 | JAK2 | ||
| IPH-2316 | Preclinical | VEGF | ||
| Zorinesiran | Phase 1/2 | BCL-2 | ||
| Darafutibatinib | Approved | FLT3 | ||
| Nidaglumide | Approved | C5 | ||
| Datocagene | Phase 2 | Aβ | ||
| SUV-9449 | Phase 3 | FcRn | ||
| BIO-IIT-742 | Phase 3 | CD19 | ||
| THA-9190 | Preclinical | WEE1 | ||
| SIR-IIT-176 | Preclinical | KIF18A | ||
| Tixasotorasib | NDA/BLA | CD19 | ||
| Elratuximab | NDA/BLA | PI3Kα | ||
| Kemacapivasertib | Phase 2/3 | MDM2 |
Trials (41)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06356319 | Ceviglumide | NDA/BLA | Completed |
| NCT07395879 | Zanutinib | Phase 2/3 | Active |
| NCT04637436 | NVO-9630 | Phase 2 | Terminated |
| NCT08287400 | NVO-9630 | Phase 2 | Recruiting |
| NCT06821382 | Voxacagene | Phase 2/3 | Terminated |
| NCT03566261 | Rimaglumide | Phase 1/2 | Completed |
| NCT07210864 | BII-4342 | Phase 2/3 | Recruiting |
| NCT07307636 | IDY-3466 | NDA/BLA | Recruiting |
| NCT08348829 | EXA-971 | Phase 2 | Recruiting |
| NCT07409942 | Tezesertib | Phase 1 | Terminated |
| NCT06095932 | Adagravorutinib | Phase 3 | Recruiting |
| NCT04579720 | Adagravorutinib | Phase 3 | Completed |
| NCT05270941 | NCI-IIT-878 | Approved | Active |
| NCT08050940 | STA-IIT-542 | Phase 2/3 | Active |
| NCT03565942 | RIN-582 | Phase 3 | Completed |
| NCT06440126 | RIN-582 | Phase 3 | Terminated |
| NCT05462489 | RIN-582 | Phase 3 | Completed |
| NCT08587352 | RIN-582 | Phase 3 | Completed |
| NCT03957454 | Polazasiran | Phase 3 | Completed |
| NCT08515799 | Polazasiran | Phase 3 | Active |